Study on Association between Oral Mucosal Diseases, Oral Symptoms, and Inflammatory Bowel Disease

doi:10.13701/j.cnki.kqyxyj.2020.04.019

Abstract

Abstract: Objective: To study the association between activity, duration, and drug therapy of inflammatory bowel disease (IBD) and oral mucosal diseases and oral symptoms. Methods: In this cross-sectional study, questionnaires and oral mucosal examinations were conducted among 389 IBD patients [265 with Crohn’s disease (CD) and 124 with ulcerative colitis (UC)] and 265 healthy controls. Chi-square tests and logistic regression were used to analyse the data. Results: The prevalence of fissured tongue in CD patients was higher than controls (P=0.021), and the risk increased by 7.76 times. Compared with controls, CD and UC patients had higher incidence of xerostomia and halitosis (P<0.05), and the risk of xerostomia increased by 1.98 times and 1.48 times, respectively, and the risk of halitosis increased by 0.96 times and 0.72 times, respectively. Active CD had higher prevalence of recurrent aphthous ulcer and fissured tongue compared with that in remission (P=0.048, P=0.009). The prevalence of oral lichen planus increased over the duration of CD patients (P=0.035). The detection rate of abnormal oral mucosa in CD patients treated with aminosalicylate was higher than that in immunosuppressive patients (P=0.003). Conclusion: Patients with IBD have higher risk of oral mucosal diseases and oral symptoms, which are associated with IBD activity, duration, and drug therapy, and require oral health education and multidisciplinary treatment

Key words: oral mucosal disease, oral symptom, inflammatory bowel disease, Crohn’s disease, ulcerative colitis

ZHANG Limin, ZHOU Jiamin, ZHANG Han, LU Yunyang, WEI Xiaoyu, ZHANG Xinfang, CHEN Baili, YANG Junying. Study on Association between Oral Mucosal Diseases, Oral Symptoms, and Inflammatory Bowel Disease[J]. Journal of Oral Science Research, 2020, 36(4): 387-392.

References

[1] Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease[J]. Lancet, 2018,390(10114):2741-2742.
[2] Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2015, 21(8):1982-1992.
[3] Lauritano D, Boccalari E, Stasio DD, et al. Prevalence of oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: A systematic review[J]. Diagnostics (Basel), 2019, 9(3):77-92.
[4] Gomollón F, Dignass A, Annese V, et al. Third European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016. Part 1: diagnosis and medical management[J]. J Crohns Colitis, 2016, 11(1):3-25.
[5] Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders[J]. J Crohns Colitis, 2017, 11(6):649-670.
[6] Yeung CA. Oral health surveys: Basic methods[M]. 5th edition.British Dental Journal, 2014.
[7] 陈谦明. 口腔黏膜病学[M]. 北京: 人民卫生出版社, 2012.
[8] 王红梅, 乔树芳. 增殖性化脓性口炎[J]. 国际口腔医学杂志, 2013,40(6):826-828.
[9] Rautava J, Pinnell LJ, Vong L, et al. Oral microbiome composition changes in mouse models of colitis[J]. J Gastroenterol Hepatol, 2015, 30(3):521-527.
[10] Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver[J]. PLoS One, 2015,10(7):e0134234.
[11] Muhvi-Urek M, Tomac-Stojmenović M, MijandruŠi-Sini B. Oral pathology in inflammatory bowel disease[J]. World J Gastroenterol, 2016, 22(25):5655-5667.
[12] de Vries S, Tan C, Bouma G, et al. Salivary function and oral health problems in Crohn's disease patients[J]. Inflamm Bowel Dis, 2018, 24(6):1361-1367.
[13] Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease[J]. Cochrane Database Syst Rev, 2019, 6(6):CD008414.
[14] Curkovic I, Egbring M, Kullak-Ublick GA. Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates[J]. Dig Dis, 2013, 31(3-4):368-373.
[15] Li X, Song P, Li J, et al. The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: A systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2017,14(3):238-249.
[16] Laranjeira N, Fonseca J, Meira T, et al. Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients[J]. Arq Gastroenterol, 2015, 52(2):105-110.
[17] Elahi M, Telkabadi M, Samadi V, et al. Association of oral manifestations with ulcerative colitis[J]. Gastroenterol Hepatol Bed Bench, 2012, 5(3):155-160.
[18] Brito F, de Barros FC, Zaltman C, et al. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis[J]. J Clin Periodontol, 2008, 35(6):555-560.
[19] Grössner-Schreiber B, Fetter T, Hedderich J, et al. Prevalence of dental caries and periodontal disease in patients with inflammatory bowel disease: a case-control study[J]. J Clin Periodontol, 2006, 33(7):478-484.
[20] Mortada I, Leone A, Gerges GA, et al. Oral manifestations of inflammatory bowel disease[J]. J Biol Regul Homeost Agents, 2017, 31(3):817-821.
[21] Katz J, Shenkman A, Stavropoulos F, et al. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease[J]. Oral Dis, 2003, 9(1):34-40.
[22] Szymanska S, Lördal M, Rathnayake N, et al. Dental caries, prevalence and risk factors in patients with Crohn's disease[J]. PLoS One, 2014, 9(3):e91059.
[23] 董子昱, 张芳. 口腔扁平苔藓唾液标记物研究现状分析[J]. 口腔医学研究, 2018, 34(11):1168-1171.
[24] Kumar KM, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: A pilot study[J]. J Oral Maxillofac Pathol, 2018, 22(2):199-203.
[25] Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis[J]. Cochrane Database Syst Rev, 2015, 11(11): CD001176.